Adaptimmune Therapeutics PLC — Director's Dealing 2020

Jul 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-07-01

Reporting Person: Zaks Tal Zvi (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-01	Option to purchase Ordinary Shares	$1.67	A	144000	Acquired	2030-07-01	Ordinary Shares (144000)	Direct

Footnotes

F1: The exercise price was converted from GBP1.35 based on an exchange rate of $U.S. 1.2387 to GBP1.00. The actual exercise price will be the pounds sterling amount.